

For Research Use Only

Recombinant Human PCSK9 protein (Myc Tag, His Tag)



Catalog Number: Eg0199

Basic Information

Species:
Human

Purity:
>95 %, SDS-PAGE

Tag:
Myc Tag, His Tag

EC50:
3-12 ng/mL

Technical Specifications

Purity:
>95 %, SDS-PAGE

Endotoxin Level:
<0.1 EU/ μ g protein, LAL method

Source:
HEK293-derived Human PCSK9 protein Gln31-Gln692 (Accession# Q8NBP7) with a Myc tag and a His tag at the C-terminus.

GeneID:
255738

Accession:
Q8NBP7

Predicted Molecular Mass:
13.8 kDa (Propeptide) and 62.3 kDa (mature chain)

SDS-PAGE:
17 kDa (Propeptide) and 65-75 kDa (mature chain), reducing (R) conditions

Formulation:
Lyophilized from 0.22 μ m filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

Biological Activity

Immobilized Human PCSK9 (Myc tag, His tag) at 2 μ g/mL (100 μ L/well) can bind Biotinylated Human LDL R (GST tag) with a linear range of 3-12 ng/mL.

Storage and Shipping

Storage:
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20°C to -80°C as lyophilized proteins.
- 3 months, -20°C to -80°C under sterile conditions after reconstitution.

Shipping:
The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels.


References

1. Blanchard V, et al. (2019) Pathology. Feb;51(2):177-183.
2. Sharotri V, et al. (2012) J Biol Chem. Jun 1;287(23):19266-74
3. Canuel M, et al. (2013) PLoS One. May 13;8(5):e64145.


Synonyms

PCSK9, EC:3.4.21.-, FH3, HCHOLA3, LDLCQ1

Selected Validation Data



Purity of Recombinant Human PCSK9 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.



Immobilized Human PCSK9 (Myc tag, His tag) at 2 μ g/mL (100 μ L/well) can bind Biotinylated Human LDL R (GST tag) with a linear range of 3-12 ng/mL.

For technical support and original validation data for this product please contact

T: 027-87531629

E: Proteintech-CN@ptglab.com

W: ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.